

Contents lists available at [SciVerse ScienceDirect](http://SciVerse.ScienceDirect.com)

## Virology

journal homepage: [www.elsevier.com/locate/yviro](http://www.elsevier.com/locate/yviro)

# Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying *env* from subtype C clinical isolate through intracellular homologous recombination

Yasuhisa Fujita, Hiroyuki Otsuki, Yuji Watanabe, Mika Yasui, Takeshi Kobayashi, Tomoyuki Miura\*, Tatsuhiko Igarashi\*\*

Laboratory of Primate Model, Experimental Research Center for Infectious Diseases, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

## ARTICLE INFO

## Article history:

Received 19 August 2012

Returned to author for revisions

10 September 2012

Accepted 29 October 2012

Available online 6 December 2012

## Keywords:

Intracellular homologous recombination

Simian-human immunodeficiency virus

Clinical isolate

Subtype C

CCR5-tropism

*In vitro* passage

Alveolar macrophage

*In vivo* passage

Animal model

AIDS

## ABSTRACT

A new simian-human immunodeficiency virus (SHIV), carrying *env* from an uncloned HIV-1 subtype C clinical isolate (97ZA012), was generated through intracellular homologous recombination, a DNA repair mechanism of the host cell. PCR fragments amplified from an existing SHIV plasmid (a 7-kb fragment from the 5' end and a 1.5-kb fragment from the 3' end) and a 4-kb fragment amplified from 97ZA012 cDNA containing *env* were co-transfected to human lymphoid cells. The resulting recombinant was subjected to serial passage in rhesus peripheral blood mononuclear cells (RhPBMCs). The resulting SHIV 97ZA012 was replication competent in RhPBMCs and monkey alveolar macrophages, and possessed CCR5 preference as an entry co-receptor. Experimental infection of rhesus macaques with SHIV 97ZA012 caused high titers of plasma viremia and a transient but profound depletion of CD4<sup>+</sup> T lymphocytes in the lung. Animal-to-animal passage was shown to be a promising measure for further adaptation of the virus in monkeys.

© 2012 Elsevier Inc. All rights reserved.

## Introduction

Human immunodeficiency virus (HIV) infections have been a major global public health issue since their initial recognition in the 1980s. Globally, approximately 33 million individuals are living with HIV, 1.8 million people die of HIV-related complications, and 2.6 million people newly acquired the virus in 2009 (UNAIDS, 2010). Establishment of effective preventive measures is urgently needed to control the epidemic.

Extensive genomic diversity is a characteristic trait of HIV. HIV type 1 (HIV-1), the major genotype of the virus, comprises four subgroups: M, N, O, and P. Subgroup M further comprises numerous subtypes and circulating recombinant forms (CRFs),

which are recombinant viruses among subtypes. Among the subtypes, subtype C plays a leading role in the epidemic, accounting for nearly 50% of global HIV infections (Hemelaar et al., 2011). Greater numbers of viral particles are detected in the vaginal secretions of pregnant individuals infected with subtype C than from persons infected with subtypes A or D (John-Stewart et al., 2005), potentially making subtype C more transmissible than others and rendering it predominant in the current epidemic. A compact V1/V2 loop and threonine at 316 located in the V3 loop of Env, distinct features shared by many subtype C isolates, may contribute to preferential replication of these viruses in the genital tract (Walter et al., 2009).

The humoral immune reaction directed against subtype C virus is unequal to that directed against subtype B virus. Virus-neutralizing antibodies mounted in individuals infected with subtype C are directed against the alpha-2 helix in the Env C3 region. This region is rarely immunogenic in subtype B virus infection (Moore et al., 2008), indicating a conformational difference in Env between these subtypes. The development of a tractable animal model for subtype C is thus necessary to establish a strategy for effective induction of neutralizing antibodies directed against the protein of this particular subtype.

\* Corresponding author at: Room 303, Molecular Biology Research Bldg., Institute for Virus Research, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo ward, Kyoto, Kyoto 606-8507, Japan. Fax: +81 75 761 9335.

\*\* Corresponding author at: Room 301, Molecular Biology Research Bldg., Institute for Virus Research, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo ward, Kyoto, Kyoto 606-8507, Japan. Fax: +81 75 761 9335.

E-mail addresses: [tmiura@virus.kyoto-u.ac.jp](mailto:tmiura@virus.kyoto-u.ac.jp) (T. Miura), [igarashi@virus.kyoto-u.ac.jp](mailto:igarashi@virus.kyoto-u.ac.jp) (T. Igarashi).

Simian-human immunodeficiency virus (SHIV) carrying Env derived from subtype C would be an especially vital tool because it would allow for evaluation of the effectiveness of vaccine-induced immunity in the context of virus infection *in vivo*.

However, only a few subtype C SHIVs are available, and none reproducibly replicates to high titers and induces disease in monkeys. In addition, limited numbers of SHIVs utilize the CCR5 molecule as an entry co-receptor. The scarcity of available SHIV strains is attributed to the difficulty in generating an infectious chimeric virus. SHIVs have been generated through recombinant DNA techniques involving implantation of a chunk of genes, such as *tat*, *rev*, *vpu*, and *env*, from the molecular clone of parental HIV-1 into the backbone of the SIV239 molecular clone. This method does not always lead to successful generation of infectious SHIV. Two presumable reasons may explain this difficulty: (1) incompatibility of a particular clone from the parental HIV-1 swarm with the SIV backbone and (2) inadequate employment of “breakpoints,” sites of recombination, for the given parental clones of HIV-1 and SIV. The generation of SHIVs by the conventional technique (*i.e.*, recombination of HIV-1 genes from a molecular clone verified to be infectious to human cells with an SIV backbone at breakpoints that are reasonably assumed to be appropriate) may represent a major bottleneck for the development of new SHIV strains.

Intracellular homologous recombination (IHR) is a cellular mechanism for the restoration of DNA double-strand breaks. It also takes place when exogenously introduced DNA fragments share “homologous sequences” (Srinivasan et al., 1989). The mechanism has been attributed to the generation of infectious HIV-1 particles from cell lines carrying multiple defective provirus genomes (Inoue et al., 1991). IHR also causes generation of infectious HIV-1 through co-transfection of truncated viral cDNA clones into the cells (Kalyanaraman et al., 1988; Srinivasan et al., 1989) or through recombination between exogenous sequences and integrated chromosomal HIV sequences (Clavel et al., 1989; Srinivasan et al., 1989). It is then utilized as a measure to readily generate recombinant HIV-1 (Cheng-Mayer et al., 1990; Hertogs et al., 1998; Kellam and Larder, 1994).

We reasoned that generation of SHIV through IHR could circumnavigate the above-mentioned issues and accelerate the process as follows: (1) DNA fragments prepared by polymerase


chain reaction (PCR) with cDNA from an uncloned HIV-1 genome would provide a continuum of heterogeneous sequences that potentially contain competent clone(s) in the context of infection in monkey cells *in vitro* and monkeys *in vivo* when combined with an SIV backbone, and (2) random occurrence of IHR within “homologous sequences” would likely produce multiple SHIV genomes with breakpoints at various sites, increasing the chance for emergence of a virus with favorable fitness. In addition, co-transfection of DNA fragments into cells susceptible to viral infection would subject the generated recombinant virus to multi-round replication, causing selection/evolution of a replication-competent virus. Based on this reasoning, we embarked on IHR-mediated generation of SHIV to investigate the utility of these potential advantages.

## Results

### Generation of recombinant virus through IHR

To generate a novel SHIV carrying the *env* gene derived from a clinical isolate of subtype C HIV-1 through IHR, we prepared three DNA fragments by PCR as depicted in Fig. 1. Approximately 1100 bps of overlapping sequence (where IHR was expected to take place) were shared by Fragments I and III, 1400 bps were shared by Fragments II-a and III, and 1200 bps were shared by Fragments II-b and III (Fig. 1).

Although we envisioned that recombination between the two DNA fragments could theoretically take place at any base within these overlaps, potentially resulting in generation of multiple sets of recombinant genomes, only replication-competent recombinant(s) would emerge as representative following transfection with these fragments into susceptible cells for lentiviral replication and multi-round replication cycles. To test this hypothesis, mixtures of Fragments I, II-a, and III (Transfection #1) or Fragments I, II-b, and III (Transfection #2), 0.2 µg of each DNA preparation, were co-transfected to human T-lymphoid cell line C8166-CCR5 cells. The cultures were maintained for 3 weeks to monitor emergence of recombinant virus by microscopic observation because the parental HIV-1 97ZA012, which contributed the *env* gene to the transfection, was known to induce syncytia in the cells (data not shown). Transfection #1 produced syncytia on day



**Fig. 1.** Schematic representation of HIV-1/SHIV genome organizations and PCR fragments employed for co-transfection. Filled boxes represent genes derived from SIV. Open boxes represent genes derived from HIV-1. SHIV KS661, existing SHIV, carries *tat*, *rev*, *vpu*, and *env* genes from subtype B HIV-1 89.6. Broad lines represent PCR fragments; Fragments I and II-a/II-b were amplified using plasmid DNA of SHIV KS661 as a template. Fragment III was amplified from cDNA of the HIV-1 97ZA012 genome as a template. Arrows represent PCR primers whose identifiers are depicted in the figure.


14 post-transfection, and Transfection #2 caused syncytia on day 15. A small portion of each culture was collected on the day of syncytia emergence and co-cultivated with uninfected C8166-CCR5 cells to determine whether the syncytia would spread. Both initiated robust syncytia formation within 24 h post co-cultivation, suggesting generation of a recombinant virus capable of replicating in C8166-CCR5 cells. Culture supernatants collected at 3 days post-co-culture, viz. 17 days post-Transfection #1 and 18 days post-Transfection #2, were combined and used as starting material for *in vitro* selection/adaptation.

#### *In vitro* passage of the recombinant virus

Because we aimed to generate a new SHIV strain to be used in a macaque model, which requires a virus with the capacity to replicate to a high titer, we first subjected the “syncytium-inducing agent,” which emerged through IHR, to sequential passage in rhesus macaque PBMCs (RhPBMC). We envisioned that a certain population of the recombinant carrying a suitable genotype from the parental virus swarm and appropriate recombination breakpoints might outgrow and/or evolve through the passage. Newly generated recombinant viruses are known in general to be less replication competent, especially in RhPBMCs. Such viruses have replicated better when inoculated into CD4<sup>+</sup>

cell-enriched RhPBMCs by deletion of CD8<sup>+</sup> cells (Chen et al., 2000; Kamada et al., 2006). Although the viral agent was robustly replicating in human C8166-CCR5 cells, we followed the previous observations and inoculated 100  $\mu$ l filtered culture supernatant of the cells into  $2 \times 10^6$  rhesus macaque CD4<sup>+</sup> cell-enriched RhPBMCs (Passage #1). Virus replication was monitored by virion-associated reverse transcriptase (RT) activity released in the culture supernatant (Fig. 2).

Passage #1 revealed that the virus indeed replicated in CD4<sup>+</sup> cell-enriched RhPBMCs (Fig. 2A). The virus replicated to an initial peak of RT activity on day 3 with 2000 cpm/ $\mu$ l supernatant equivalent, and replication was then reduced somewhat on day 4 (1250 cpm), likely because of the addition of fresh CD4<sup>+</sup> cell-enriched PBMCs. Replication increased again to 2170 cpm on day 5, the highest RT activity in this passage. The RT activity was maintained at a high level during the subsequent 2 days (1900–2000 cpm), then declined rapidly on day 8. Cryopreserved culture supernatant (50  $\mu$ l) collected from day 5 of Passage #1 was inoculated to  $2 \times 10^6$  newly prepared CD4<sup>+</sup> cell-enriched RhPBMCs to confirm the observed replication property of the virus (Passage #2). Although replication in Passage #2 took longer than that in Passage #1, the Passage #2 virus also replicated to a high titer, 2180 cpm/ $\mu$ l supernatant equivalent on day 8, followed by a sharp decline on day 9 (1250 cpm; Fig. 2B).



**Fig. 2.** Passage of the recombinant virus through RhPBMCs. Recombinant virus that emerged from C8166-CCR5 cells co-transfected with PCR fragments was serially passed through RhPBMCs (A–E). A small amount of supernatant was collected from each culture daily, and virion-associated reverse transcriptase (RT) activity was assessed. RT activities were represented as radioactive counts per minute (cpm) induced by 1  $\mu$ l culture supernatant equivalent. CD4<sup>+</sup> cell-enriched RhPBMCs were employed for Passages #1–3 (A–C), and whole RhPBMCs were utilized for Passages #4 and #5 (D and E). Filtered culture supernatant was used to pass virus from existing culture to new culture, except from Passage #2 to #3, in which the mixture of cells and supernatant was inoculated to freshly prepared cells.


Because the virus appeared to reproducibly replicate in CD4<sup>+</sup> cell-enriched RhPBMCs, we next examined whether the virus could replicate in unmanipulated RhPBMCs, a cell preparation without enrichment of CD4<sup>+</sup> cells, by taking a small portion of the ongoing culture on day 8 and co-cultivating it with fresh whole RhPBMCs (Passage #3). For this experiment, we monitored the RT activity of the culture supernatant from Passage #2 daily and decided to set up Passage #3 because of a substantial increase in RT activity on day 8. Passage #3 resulted in robust virus replication that reached 5,250 cpm/ $\mu$ l supernatant equivalent on day 7, then declined during the following days, suggesting that it possessed replication capacity in unmanipulated RhPBMCs (Fig. 2C). To determine whether we could reproduce this observation in a more rigorous setting, culture supernatant without cells, collected on day 7 from Passage #3, was inoculated into whole RhPBMCs newly prepared from normal rhesus macaques (Passage #4). The virus replicated robustly to a high titer, reaching 1850 cpm/ $\mu$ l supernatant equivalent on day 5, followed by a rapid decline (Fig. 2D). To confirm the observation, we inoculated supernatant collected on day 5 of Passage #4 into another RhPBMC preparation without manipulation a second time (Passage #5). The virus reproducibly replicated in primary monkey cells, with a peak of RT activity on day 5 post-infection (2280 cpm;

Fig. 2E). We concluded that a new recombinant virus capable of replicating in RhPBMCs was generated/evolved through IHR/*in vitro* passage. We designated the culture supernatant collected on day 5 from Passage #5 as SHIV 97ZA012 and subjected it to further characterization.

#### Genomic organization of SHIV 97ZA012

To elucidate the genomic organization of SHIV 97ZA012, the nt sequence was determined on cDNA that was reverse-transcribed from virion-associated viral genomic RNA prepared from the culture supernatant. The obtained sequence was compared with those of SHIV KS661 and HIV-1 97ZA012 (Fig. 3). Genomic analysis revealed that the 5' and 3' breakpoints were at the 282nd nt of *env* gp120, upstream of the V1/V2 loop, and the 756th nt of the *env* gp41 cytoplasmic domain, respectively (Fig. 3A). The breakpoints that gave rise to replication-competent virus were not necessarily at the interface of genes juxtaposed to each other. This is also the case in many CRFs of HIV-1, examples of naturally occurring recombinants (Carr et al., 2001; Guimaraes et al., 2008; Koulinska et al., 2001; Perez et al., 2006; Piyasirisilp et al., 2000).

SimPlot (Lole et al., 1999) analysis revealed that the genomic fragment derived from HIV-1 97ZA012 did not completely match



**Fig. 3.** Genomic organization of SHIV 97ZA012. (A) Breakpoints in SHIV 97ZA012 were analyzed by the SimPlot program with SHIV KS661 (gray) and HIV-1 97ZA012 (black) as references. Schematic SHIV genome organization was aligned to similarity plot for a visual purpose. (B) Phylogenetic analysis of SHIV 97ZA012 *env* portion. The gene portion identified in (A), between nt 6429 and 8325 (in HIV-1 HXB2) and derived from HIV-1 97ZA012, was subjected to phylogenetic analysis with the corresponding sequence of the reference virus isolates. The phylogenetic tree was generated by the neighbor-joining method.



the registered sequence of the virus (GenBank Accession No. AF286227). To ascertain that the recombinant virus indeed carries the *env* sequence derived from HIV-1 97ZA012, we conducted a phylogenetic analysis of the sequence with the corresponding region of HIV-1 strains belonging to subtype B or C, including the registered sequence of 97ZA012 (Fig. 3B). The supposed 97ZA012-derived sequence naturally formed a subcluster with the registered sequence and was positioned in the cluster of subtype C strains in the phylogenetic tree. We concluded that the observed difference in sequences between SHIV 97ZA012 and the registered HIV-1 97ZA012 was within the extent of quasiespecies of a single isolate.

#### Replication properties of SHIV 97ZA012 in C8166-CCR5 cells and RhPBMCs

To characterize the replication properties of SHIV 97ZA012, we inoculated the virus into human C8166-CCR5 cells and RhPBMCs. Because HIV-1 is unable to replicate in monkey cells, the relative replication capability of the newly generated virus to the parental HIV-1 97ZA012 was assessed in C8166-CCR5 cells. SHIV KS661, which provided the backbone for SHIV 97ZA012, was also examined. In RhPBMCs, replication of SHIV 97ZA012 was compared with that of SIV239, the most widely used SIV. The viruses were normalized to an infectious unit (multiplicity of infection [MOI]=0.01 or 0.1 median tissue culture infective dose [TCID<sub>50</sub>/cell]) and inoculated into these cells. Replication of the viruses was monitored by virion-associated RT activity in the culture supernatant (Fig. 4). Because C8166-CCR5 cells were highly susceptible to HIV-1/SIV and progressed to cell death, infections at a higher multiplicity (MOI=0.1) resulted in lower peak RT activities compared with those at a lower multiplicity (Fig. 4A). Regardless of multiplicity, SHIV 97ZA012 exhibited a slower replication kinetic compared with that of the parental HIV-1

97ZA012, likely due to the chimeric structure of the virus (Li et al., 1992; Shibata et al., 1991) or to the result of adaptation to monkey cells. SHIV KS661 also exhibited faster replication kinetics compared with SHIV 97ZA012.


While SHIV 97ZA012 exhibited a slower replication profile compared with the reference viruses in C8166-CCR5 cells, replication of SHIV 97ZA012 in RhPBMCs was comparable with that of SIV239 (Fig. 4B). Infection at a MOI=0.01 resulted in somewhat more production of progeny in SIV239 than in SHIV 97ZA012 during the first 3 days. When the experiment was set up at a MOI=0.1, SIV239 produced markedly more progeny than did SHIV 97ZA012 during the first 3 days of infection, while SHIV 97ZA012 replicated to higher titers than did SIV239 at day 4 and thereafter. To estimate the total production of progeny virus during the observation period, the areas under the curve (AUC) of each virus were compared. The AUC of SHIV 97ZA012 was approximately 1.5-fold greater than that of SIV (data not shown). Based on these data, we concluded that SHIV 97ZA012 is as replication competent as SIV239 in rhesus macaque PBMCs.

#### Co-receptor preference of SHIV 97ZA012


The parental HIV-1 97ZA012 strain reportedly utilizes CCR5 as an entry co-receptor (Broder and Jones-Trower, 1999). The chimeric structure of gp120 carried by SHIV 97ZA012 (between KS661, which was originally derived from HIV-1 89.6, and 97ZA012) and uncertainty of the co-receptor preference of 97ZA012 Env in the context of the SHIV/macaque cell system prompted us to subject SHIV 97ZA012, along with control viruses, to a co-receptor usage assay. Each virus, normalized by an infectious unit, was inoculated to RhPBMCs in the presence of 5  $\mu$ M AMD3100 (a small-molecule CXCR4 inhibitor), AD101 (a small-molecule CCR5 inhibitor), or both. Virus replication was monitored for 7 days by virion-associated RT activity release in the culture supernatant (Fig. 5). SIV239, which has been established as a CCR5-utilizing virus, replicated to a high titer in the absence of any inhibitor (Fig. 5A). AMD3100 had little impact on the replication of the virus, as described previously (Zhang et al., 2000). In the presence of AD101 or both inhibitors, however, replication of SIV239 was substantially impaired. In contrast, SHIV KS661, which has been reported to predominantly utilize CXCR4 as an entry co-receptor (Matsuda et al., 2010), exhibited a replication profile opposite to that of SIV239: no impairment of replication in the presence of AD101, but remarkably delayed replication in the presence of AMD3100, and complete suppression in the presence of both inhibitors (Fig. 5B). When control viruses exhibited the replication profiles described above, SHIV 97ZA012 exhibited a replication profile similar to that of SIV239: no impact on replication in the presence of AMD3100, but complete suppression when AD101 was present in the culture (Fig. 5C). Based on these results, we concluded that SHIV 97ZA012 is a CCR5-utilizing virus, as is the parental HIV-1 97ZA012 in human cells.

#### Replication of SHIV 97ZA012 in macrophages

Many CCR5-utilizing HIV-1 strains replicate in monocyte-derived macrophages, which is a biological property called “macrophage tropism.” Macrophage tropism has been shown to be associated with viral neurotropism (Gorry et al., 2001), a subject to be investigated in non-human primate AIDS models. To clarify the biological property of the virus in macrophages, SHIV 97ZA012, along with macrophage-tropic and non-macrophage-tropic viruses, normalized by RT activity was inoculated to rhesus macaque primary alveolar macrophage (RhAM) cultures prepared from three uninfected animals. Virus replication was monitored by virion-associated RT activity released in



**Fig. 4.** Replication of SHIV 97ZA012 in C8166-CCR5 cells (A) and RhPBMCs (B). The replication property of SHIV 97ZA012 in these cells was compared with those of HIV-1 97ZA012, SHIV KS661 (A) and SIV239 (B). The viruses were normalized by the infectious unit (MOI=0.01 and 0.1 TCID<sub>50</sub>/cell) and spinoculated to these cells at 1200 × g for 60 min. Gray symbols/lines represent virus replication at MOI=0.01, and black symbols/lines represent virus replication at MOI=0.1. Culture supernatant was collected daily, and virion-associated reverse transcriptase activities were assessed.




**Fig. 5.** Co-receptor usage of SHIV 97ZA012. SHIV 97ZA012, along with CCR5-tropic SIV239 and predominantly CXCR4-tropic SHIV KS661, was inoculated into RhPBMCs in the presence of small-molecule co-receptor inhibitor(s) (5  $\mu$ M), and replication was assessed by reverse transcriptase activity in the culture supernatant for 7 days. The following compounds were utilized as co-receptor inhibitors: AMD3100 for anti-CXCR4 inhibitor and AD101 for anti-CCR5 inhibitor, which was kindly provided by Dr. Julie Strizki, Schering-Plough Research Institute, Kenilworth, NJ.

the culture supernatant (Fig. 6). Overall, the viruses exhibited consistent replication profiles among cell cultures prepared from different individuals (Fig. 6A–C). SIV316, a macrophage-tropic variant of SIV239 (Desrosiers et al., 1991), replicated to the highest titers among the viruses, reaching a peak around days 7–9 post-infection (2000–2500 cpm/ $\mu$ l). SHIV  $\lambda$ 3-3, a macrophage-tropic SHIV (Igarashi et al., 2007), exhibited a delayed replication profile and reached titers of > 1000 cpm/ $\mu$ l after 17 days post-infection. In contrast, SIV239, which is reportedly incapable of replicating in cells of this type (Mori et al., 1993), produced no measurable RT activity in the supernatant during the observation period. Under this condition, SHIV 97ZA012 replicated productively, although not as robustly as SIV316 or SHIV  $\lambda$ 3-3, and reached peak virus replication on day 9 post-infection (400–600 cpm/ $\mu$ l). Based on these results, we concluded that SHIV 97ZA012 is macrophage tropic.

#### Experimental infection of rhesus macaques with SHIV 97ZA012


Biological properties of the newly generated SHIV 97ZA012 revealed in the study, including CCR5 utilization, a robust



**Fig. 6.** Replication of SHIV 97ZA012 in primary rhesus alveolar macrophages (RhAMs). SHIV 97ZA012, along with macrophage-tropic SIV316 and SHIV  $\lambda$ 3-3 and non-macrophage-tropic SIV239, was inoculated into primary RhAMs, and its replication was monitored for 3 weeks. RhAMs were prepared from three animals independently (A–C). Virus replication was assessed by reverse transcriptase activity in the culture supernatant.

replication profile in RhPBMCs, and infectiousness in primary macrophages, justified experimental infection of monkeys with the virus. Prior to the infection, we prepared an ample volume of animal challenge stock of the virus by inoculating SHIV 97ZA012 seed to RhPBMCs. Culture supernatant was collected daily and assessed for virus replication by RT activity. Fractions of culture supernatant collected on days 8 and 9 that exhibited the highest RT activities (2450 and 2550 cpm/ $\mu$ l supernatant equivalent) were combined, filtered through a 0.45- $\mu$ m membrane, divided into aliquots designated SHIV 97ZA012 animal challenge stock, and stored in liquid nitrogen. The infectious titer of the virus stock was  $1.51 \times 10^4$  TCID<sub>50</sub>/ml, and retention of its preference for CCR5 as an entry co-receptor was verified (data not shown).

The animal challenge stock of SHIV 97ZA012,  $1 \times 10^5$  TCID<sub>50</sub>, was intravenously inoculated into each of three rhesus macaques. Virus replication was monitored by viral RNA load in plasma samples that were collected periodically (Fig. 7). The virus replicated to substantially high titers in all three animals, reaching an initial peak of  $1.03 \times 10^8$  copies/ml for MM533,  $4.52 \times 10^6$  copies/ml for MM535, and  $1.83 \times 10^8$  copies/ml for MM536 at week 1.1 (day 8) post-inoculation (Fig. 7A). After the initial peak,



**Fig. 7.** Experimental infection of rhesus macaques with SHIV 97ZA012.  $1 \times 10^5$  TCID<sub>50</sub> SHIV 97ZA012 animal challenge stock was intravenously inoculated into three rhesus macaques, MM533, MM535, and MM536. Their plasma viral burdens (A), circulating CD4<sup>+</sup> T lymphocytes (B), and CD4<sup>+</sup> T cells in the alveolar space (C) were monitored periodically. Lymph node cells and whole blood collected from MM535 and MM536 at week 10.7 were transferred to MM554 (A–C).

viral burdens of all three animals declined somewhat, but remained at approximately  $1 \times 10^6$  copies/ml between weeks 3 and 5. One of the animals, MM533, was found to be lethargic and subsequently died at week 4. The cause of death was not related to primate lentivirus infection. The plasma viral burdens of the remaining two animals gradually declined from week 6 onward, resulting in barely detectable levels at week 20 (650 copies/ml for MM535 and 740 copies/ml for MM536).

(Fig. 7B). Although all three animals experienced a transient decrease in cell numbers, the cell numbers promptly rebounded thereafter and basically stabilized after week 8 for MM535 and week 6 for MM536.

SIV and HIV-1 preferentially replicate at an “effector site,” such as the mucosal tissues of the genital organs, lung, and gastrointestinal tract, where CCR5-positive effector memory CD4<sup>+</sup> T lymphocytes, the primary viral target cells, predominantly reside. Here, they cause substantial depletion of cells during the acute phase of infection (Brenchley et al., 2004; Okoye et al., 2007; Veazey et al., 1998; Veazey et al., 2003). Because SHIV 97ZA012 utilizes the CCR5 molecule as an entry coreceptor, it was envisaged that the virus depletes effector memory CD4<sup>+</sup> T lymphocytes as do SIV and HIV-1. We examined the fluctuation in CD4<sup>+</sup> T lymphocytes in the pulmonary space of SHIV 97ZA012-infected

animals as the representative effector site because the procedure causes the least severe insult to animals, allowing us to conduct frequent monitoring. It is known that SIV239 infection results a substantial depletion of pulmonary CD4<sup>+</sup> T cells in infected rhesus macaques, along with depletion of the cells in the gastrointestinal tract (Okoye et al., 2007). In contrast to the cells in circulation, CD4<sup>+</sup> T cells in the alveolar space exhibited a substantial decline during the acute phase of SHIV 97ZA012 infection (Fig. 7C). The percentages of cells dropped from 48.5%, 52.1%, and 44.7% for MM533, MM535, and MM536, respectively, on day 0 to 6.3% for MM533 at week 2.7, 16.8% for MM535 at week 5, and 2.6% for MM536 at week 2.7. The alveolar CD4<sup>+</sup> T lymphocytes remained at low levels in the animals until week 11, then gradually increased toward pre-infection levels. Based on the results described above, it was concluded that SHIV 97ZA012 robustly replicated during the acute phase of infection, causing remarkable reduction of CD4<sup>+</sup> T cells in the alveolar space. However, the animals eventually controlled the virus replication. SHIV 97ZA012 thus appeared to be less likely to cause disease in monkeys.

Multiple reports on the evolution of primate lentivirus through animal-to-animal passage have shown that initially less-efficiently replicating and non-pathogenic viruses transform to replication-competent and highly pathogenic viruses (Joag et al., 1996; Reimann et al., 1996a; Sharma et al., 1992). We applied this strategy to SHIV 97ZA012. At week 10.7, the axillary lymph nodes were collected from animals MM535 and MM536. Cells prepared from the lymph nodes from both animals,  $5 \times 10^8$  cells in total, were resuspended with 10 ml anti-coagulated whole blood collected simultaneously from these monkeys. The resuspension was intravenously transferred to another rhesus macaque, MM554. The virological and immunological parameters of the recipient animal were monitored as described above. The virus induced viremia with an initial peak of  $4.2 \times 10^8$  copies/ml at week 1.6, followed by a gradual decrease until week 8, then was maintained at approximately  $3\text{--}4 \times 10^5$  copies/ml for 4 weeks (Fig. 7A). Although the plasma viral burden of MM554 declined after the initial peak, its titer was constantly higher than those inoculated with the original animal challenge stock of SHIV 97ZA012, indicating likely improvement in virus replication. Numbers of circulating CD4<sup>+</sup> T lymphocytes in MM554 did not change substantially compared with the other animals (Fig. 7B). MM554 manifested a more substantial reduction in alveolar CD4<sup>+</sup> T cells than did the other three animals (Fig. 7C). The percentage of CD4<sup>+</sup> T lymphocytes dropped from 61% at day 0 to 2.8% at week 3, and further declined to 1.4% at week 5. The cell numbers remained low until week 7 and started to recover thereafter. Based on these results, we concluded that animal-to-animal passage appears to have made SHIV 97ZA012 more fit to replicate in macaque monkeys, warranting improvement by further passage.

## Discussion

In this study, we successfully generated a new SHIV strain carrying Env derived from an HIV-1 subtype C primary isolate, HIV-1 97ZA012, utilizing IHR. The presumable advantages of the method employed in the current study over conventional methods utilizing existing/newly generated restriction sites are random utilization of breakpoints within homologous sequences and selection of replication-competent recombinants through multi-round replication in the susceptible cells. These factors may have contributed to the generation of the new SHIV in the current study.

Initially, SHIVs have been generated through recombination of infectious molecular clones of SIV and HIV-1 (Shibata et al., 1991 #143; Li et al., 1992 #141; Luciw et al., 1995 #152; Reimann



et al., 1996b #153). The availability of HIV-1 infectious molecular clone(s) was thus a prerequisite for the generation of SHIV. The SHIVs generated in the abovementioned manner generally exhibited insubstantial replication profiles *in vitro* and *in vivo* (Shibata et al., 1991 #143; Li et al., 1992 #141; Sakuragi et al., 1992 #151; Luciw et al., 1995 #152; Reimann et al., 1996b #153). Plasmid clones carrying open reading frames that were derived from PCR fragments amplified from HIV-1 provirus were subsequently employed as the source of HIV-1 genes, instead of DNA fragments excised from full-length molecular clones (Chen et al., 2000 #1; Kuwata et al., 2002 #135). Kuwata et al. generated 30 SHIV clones representing Env protein from three independent isolates of HIV-1 from the initial exertion to generate SHIV strains representing six separate HIV-1 isolates. Of 30 clones, three were infectious to human cells, and only one productively replicated in monkey PBMCs but exhibited only modest replication *in vivo* (Kuwata et al., 2002 #135). Hence, generation of replication-competent SHIVs by the conventional method is inefficient.

In contrast, the IHR-mediated method described in the current study generated replication-competent SHIV 97ZA012 without the requirement for an infectious molecular clone of the parental HIV-1, exploration of appropriate restriction sites, or examination of each plasmid clone for infectivity. This was performed in a considerably shorter time frame in our experience, saving several months compared with conventional methods. However, one would argue that IHR-mediated generation of SHIV does not allow for a detailed genetic analysis, such as mutagenesis of particular gene(s), because of the virus being “swarm.” While this is undeniable, the vast majority of currently available replication-competent SHIVs are resultants of evolution through animal-to-animal passage and exist as quasispecies (Joag et al., 1996 #49; Reimann et al., 1996a #52; Igarashi et al., 1999 #156; Harouse et al., 2001 #154; Song et al., 2006 #158; Nishimura et al., 2010 #157). A molecular-cloned virus representing the properties of the swarm is attainable by introduction of consensus sequences to a molecular clone, if necessary.

Co-transfection of genome fragments into C8166-CCR5 cells appears to have generated multiple recombinant viruses with distinct breakpoints and/or *env* genes. Following short-term propagation of the virus that emerged after co-transfection, viral genomic RNA from culture supernatant was subjected to sequencing without a cloning step. We were unable to determine the sequence within the overlaps between Fragments I and III or II-a/b and III (Fig. 1) because of multiple sequence peaks at each location, suggesting the existence of multiple DNA templates (data not shown). The mixture of recombinants was substantially “purified” through serial passages in RhPBMCs (Fig. 2), allowing us to determine breakpoints (Fig. 3). This observation supports the relevance of the concept employed in the current study; that is, selection of replication-competent recombinants through multi-round replication.

The selected replication-competent recombinant virus possesses breakpoints within the *env* gene, resulting in a “mosaic” *env* structure. Because primate lentiviruses encode multiple genes in different reading frames in a stratified fashion, *tat* and *rev* genes also became mosaic. The mosaic *tat*, *rev*, and *env* genes are not uncommon among circulating recombinant forms of HIV-1 (Carr et al., 2001; Koulinska et al., 2001; Ng et al., 2012; Su et al., 2000; Yamaguchi et al., 2008), although these breakpoints are less likely to be employed in rational construction of SHIVs.

SHIV 97ZA012 replicated to a titer comparable with that of SIV239 in RhPBMCs, and the observed trend was unaffected by the reduction in MOI (from 0.1 to 0.01 in Fig. 4B), an indication of the replication competence of SHIV 97ZA012 in the cells. In addition, SHIV 97ZA012 exhibited productive replication in rhesus primary alveolar macrophages, although not as robust as that

of SIV316 (Fig. 6). In our experience, not every “macrophage-tropic” virus replicates in alveolar macrophages. While SIV 251 and SIVsmE543 have been reported to be macrophage-tropic in monocyte-derived macrophages (Hirsch et al., 1997; Miller et al., 1998), they did not replicate in alveolar macrophages (Igarashi et al., unpublished). Alveolar macrophages of human or rhesus macaque express miniscule amounts of CD4 and CCR5 (Mori et al., 2000; Worgall et al., 1999). Therefore, SHIV 97ZA012 may be able to gain entry to cells expressing minimal numbers of receptors/coreceptors, as is SIV316 (Puffer et al., 2002). Whether “CD4-independence” is a property shared by many subtype-C Env or is specific to 97ZA012 or whether a “mosaic” Env protein between HIV-1 89.6 and 97ZA012 caused this notable property remains to be investigated.

This study also presents potential shortcomings of IHR to be resolved in the future. The first drawback is that only a limited variety of Env may function in the C8166-CCR5 cells utilized in the current study, resulting in generation of SHIVs reflecting this potential restriction. Prior to the current study, we inoculated nine primary isolates of HIV-1 subtype C obtained from the National Institutes of Health (NIH) AIDS Research & Reference Reagent Program into the cells and found that seven of them replicated in the cells with syncytia (data not shown). Cells susceptible to a broad range of HIV-1 primary isolates should be utilized in the future. The second shortcoming is the relatively long (2-week) “incubation phase” following co-transfection. The low frequency of recombination events and less-efficient DNA transfection may have been responsible for the elongated incubation period. Upregulation of IHR through certain means, such as overexpression of Rad51 (Vispe et al., 1998) (an enzyme that plays an important role in IHR) prior to co-transfection of viral cDNA fragments or utilization of certain cells that are shown to exhibit elevated IHR activity (e.g., breast cancer cells (Mao et al., 2009)) could augment the efficiency of recombination. To achieve higher transfection efficiency, utilization of well-established and highly transfectable cells, such as 293 T (formerly 293tsA1609neo) cells (DuBridge et al., 1987), followed by co-cultivation with cells susceptible to virus replication, such as PBMCs, should be explored.

We were able to detect syncytia formation in the culture transfected with DNA fragments only after 2 weeks. Once syncytia emerged, however, the virus replicated productively in C8166-CCR5 cells and subsequently in RhPBMCs enriched with CD4<sup>+</sup> cells and unmanipulated RhPBMCs through a passage in RhPBMCs. SHIV 97ZA012 evolved to be replication competent in RhPBMCs and infectious to RhAMs. The virus may have been replication competent in monkey cells from the beginning. Although HIV-1 97ZA012, which contributed *env* to SHIV 97ZA012, may have been predisposed to be adequate as a parental virus for generation of SHIV, we have the impression that the method we employed in this study generated a pool of recombinants and selected suitable one(s) through *in vitro* passage. As mentioned above, the recombinant virus that initially emerged was a mixture, and the final genotype(s) was selected and/or evolved through *in vitro* passage. The only traits of HIV-1 97ZA012 of which we were aware were its replication competence in human PBMCs and its preference for CCR5 as an entry co-receptor to the cells (data not shown).

SHIV 97ZA012 reproducibly replicated to high titers *in vivo* with a major reduction in pulmonary CD4<sup>+</sup> T cells during the acute phase of infection. Considering the paucity of available SHIV strains carrying subtype C Env and a CCR5 co-receptor preference in the field, the virus generated in the current study would immediately fit the interest for evaluation of anti-subtype C vaccine candidates. The virus would be especially useful when the efficacy of antiviral interventions is judged by reduction of the



initial peak viral load or prevention of virus-induced depletion of CD4<sup>+</sup> T lymphocytes in the effector sites.

Although we successfully generated an SHIV strain competent in tissue culture, the generation of a proficient virus *in vivo* remains arduous. Indeed, SHIV 97ZA012 replicated to substantially high titers during the acute phase of infection. However, the plasma viral load waned with time, as did SHIV strains generated previously. Animal-to-animal passage would augment its replication *in vivo*, as we attempted in this study.

This study has demonstrated the versatility of IHR-mediated generation of SHIV. The method enables utilization of a PCR fragment amplified from uncloned virus as a source for SHIV. This method can be further extended to generate SHIV strains with sequences amplified from clinical samples, such as patient plasma, to strengthen the panel of challenging viruses for evaluation of an anti-HIV vaccine.

## Conclusions

By employing IHR, a replication-competent SHIV carrying Env derived from a CCR5-tropic, subtype C HIV-1 97ZA012 strain was generated.

## Materials and methods

### Cells

C8166-CCR5 cells from a human T-lymphotropic virus type-1-transformed human T-lymphoid cell line that was transduced to express human CCR5 and established as described previously (Soda et al., 1999) were generously provided by Dr. Hiroo Hoshino, Gunma University, Japan. The cells were cultured in Roswell Park Memorial Institute 1640 medium (Life Technologies Corporation, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 4 mM L-glutamine, and 2 mM sodium pyruvate (R-10). RhPBMCs were prepared and cultured as described previously (Imamichi et al., 2002), with minor modification; 160 units/ml recombinant interleukin-2 (Wako Pure Chemicals, Osaka, Japan) was added to the medium to maintain lymphocytes. RhAMs were collected through a bronchoalveolar lavage technique and cultured as described previously (Imamichi et al., 2002).

### Viruses

Virus stocks of SIV239 (Kestler et al., 1988), SIV316 (Desrosiers et al., 1991), SHIV DH12R CL7 (Sadjadpour et al., 2004), and SHIV  $\lambda$ 3-3 (Igarashi et al., 2007) were propagated in RhPBMCs following inoculation with transfection supernatant of the proviral plasmid of each virus. Dr. Ronald C. Desrosiers at Harvard University kindly provided the plasmid of SIV239. Dr. Malcolm A. Martin at the National Institute of Allergy and Infectious Diseases (NIAID), NIH, generously contributed the plasmid of SIV316 with permission from Dr. Desrosiers and the plasmids of SHIV DH12R CL-7 and SHIV  $\lambda$ 3-3. Infectious titers (TCID<sub>50</sub>) of the virus stocks were determined by titration as described previously (Shibata et al., 1997), with a minor modification; the indicator cells employed for titration were RhPBMCs in this study. The HIV-1 97ZA012 isolate was obtained from The UNAIDS Network for HIV Isolation and Characterization through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, and was propagated briefly in human PBMCs after acquisition.

### Preparation of cDNA from HIV-1 97ZA012 genomic RNA

Culture supernatant was harvested from human PBMCs infected with HIV-1 97ZA012 on day 8 post-inoculation. Virion-associated RNA was extracted with the QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany), following the manufacturer's instructions. The extracted RNA was subsequently subjected to synthesis of cDNA with Super Script III (Life Technologies Corporation) following the manufacturer's instructions. For the reaction, the following primer was utilized: OFM19-R (5'-aggcaagctttattgaggctta-3' at 9604-9625 in HIV-1 HXB2).

### Generation of recombinant virus through IHR

Two segments of the SHIV genome (Fragments I and II; Fig. 1) were amplified by PCR with pSHIV KS661, an infectious molecular clone of SHIV C2/1 (Shinohara et al., 1999), as a template. Positions of PCR primers were numbered relative to the SIV239 or HIV-1 HXB2 genome sequence (GenBank accession nos. M33262 and K03455, respectively). For Fragment I, the following primer pair was employed: SIVU3Not-F forward primer (5'-atgcggccgctggaagg-gatttattacagtgcag-3', at 1–25 in SIV239) and SHenv2R rear primer (5'-cacagagtgggttaattttacac-3', at 6580–6603 in HIV-1 HXB2). Two sets of Fragment II (II-a and II-b) were amplified by PCR. For Fragment II-a, the following primer pair was used: SHenv5.5F forward primer (5'-tcataatgatagtaggagc-3', at 8278–8297 in HIV-1 HXB2) and SIVU5Eco-R rear primer (5'-tgcagaattctgctaggat-tttctgcttcggtt-3', at 10255–10279 in SIV239). For Fragment II-b, the following primer pair was utilized: SHenv6F forward primer (5'-gcggagcctgtgctcttcagc-3', at 8504–8525 in HIV-1 HXB2) and SIVU5Eco-R rear primer. A segment of the HIV-1 97ZA012 genome containing *env* and flanking genes (Fragment III) was amplified through PCR with cDNA of viral genomic RNA as a template. For amplification of Fragment III, the following primer pair was applied: HIVvpr-F forward primer (5'-agatggacaagccccagaaga-3' at 5557–5578 in HIV-1 HXB2) and OFM19-R rear primer.

All PCR reactions were conducted with the Expand Long Range dNTPack (Roche Diagnostic Corporation, Basel, Switzerland) under the following conditions: initial denaturation at 94 °C for 2 min, followed by 10 cycles of amplification consisting of denaturation at 94 °C for 15 s, annealing at 55 °C for 30 s, and extension at 68 °C for 8 min. The reaction was continued with 25 cycles of amplification consisting of denaturation at 94 °C for 15 s, annealing at 55 °C for 30 s, and extension at 68 °C for 8 min (plus 20 s at every cycle), followed by a final extension at 68 °C for 7 min.

Mixtures of Fragments I, II-a, and III (Transfection #1) or I, II-b, and III (Transfection #2), 0.2  $\mu$ g of each fragment, were co-transfected into C8166-CCR5 cells through diethylaminoethyl-dextran-mediated DNA uptake followed by osmotic shock (Takai and Ohmori, 1990). After co-transfection, the cell cultures were maintained in 24-well plates at 37 °C and monitored by daily microscopic observation. On day 14 for Transfection #1 and day 15 for Transfection #2, a small portion of each culture was taken and independently co-cultured with uninfected C8166-CCR5 cells for an additional 3 days.

### In vitro passage of recombinant virus

RhPBMCs were prepared as described above. The CD8<sup>+</sup> cell fraction was removed from the cell preparation using phycoerythrin (PE)-conjugated anti-CD8 antibody (clone SK1; BD Biosciences, San Jose, CA, USA) and anti-PE-conjugated magnetic microbeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), following the manufacturers' instructions.

Culture supernatant from C8166-CCR5 cells co-cultured with Transfection #1 or Transfection #2 on days 17 and 18 post-transfection, respectively, was mixed and filtered through a 0.45- $\mu$ m membrane. The supernatant, 100  $\mu$ l in total, was subsequently inoculated into  $2 \times 10^6$  CD4<sup>+</sup> cell-enriched RhPBMCs (Passage #1). Freshly prepared CD4<sup>+</sup> cell-enriched RhPBMCs,  $2 \times 10^6$  cells in total, were added to Passage #1 on day 3 post-inoculation. Virus replication was assessed by virion-associated RT activity in the culture supernatant, as described below. Cryopreserved supernatant on day 5 (50  $\mu$ l) from Passage #1 was thawed and inoculated into  $2 \times 10^6$  CD4<sup>+</sup> cell-enriched RhPBMCs (Passage #2). On day 3, freshly prepared CD4<sup>+</sup> cell-enriched RhPBMCs,  $2 \times 10^6$  cells in total, were added to Passage #2. The RT activity of the supernatant was monitored daily, and a small portion of Passage #2 on day 8, when the RT activity rose substantially, was subsequently co-cultured with  $2 \times 10^6$  freshly isolated RhPBMCs without enrichment of CD4<sup>+</sup> cells (Passage #3). On day 3,  $2 \times 10^6$  freshly prepared CD4<sup>+</sup> cell-enriched RhPBMCs were added to Passage #3. Cryopreserved supernatant from Passage #3 on day 7 (50  $\mu$ l) was thawed and inoculated into  $2 \times 10^6$  freshly prepared RhPBMCs without manipulation (Passage #4). On day 3,  $2 \times 10^6$  freshly prepared RhPBMCs without manipulation were added to Passage #4. Cryopreserved supernatant from Passage #4 on day 5 (50  $\mu$ l) was thawed and inoculated into  $2 \times 10^6$  freshly prepared RhPBMCs without manipulation (Passage #5). Fresh RhPBMCs without manipulation were added to Passage #5 on day 3.

#### Reverse transcriptase assay

Virion-associated RT activity in the culture supernatant was evaluated as described previously (Willey et al., 1988), with a minor modification;  $\alpha$ -<sup>32</sup>P TTP was purchased from PerkinElmer Inc. (Waltham, MA, USA) in this study.

#### Genomic analysis of the recombinant virus

Virion-associated viral genomic RNA was extracted from culture supernatant collected on day 5 of Passage #5 and reverse transcribed, as described above. For sequencing, the bulk cDNA was directly subjected to the Sanger dideoxy method with a BigDye Terminator Cycle Sequencing Kit (Life Technologies Corporation) and analyzed with an ABI PRISM 3130 Genetic Analyzer (Life Technologies Corporation).

Breakpoints of the recombinant virus were determined through comparison of sequences of the recombinant virus with those of SHIV KS661 (identical to SHIV C2/1, GenBank accession no. AF217181) and p97ZA012 (GenBank accession no. AF286227). The sequences were aligned using Clustal X software (Thompson et al., 1997) and analyzed using SimPlot software (Lole et al., 1999), with a window size of 250 bp and a step size of 20 bp.

A portion of the nt sequence of SHIV 97ZA012, at nt 6429–8325 (in HIV-1 HXB2) and derived from HIV-1 97ZA012, was subjected to phylogenetic analysis with the corresponding sequence of the following reference virus isolates: 93IN905 (GenBank accession no. AY669742), 98CN009 (AF286230), 98CN006 (AF286229), 98TZ017 (AF286235), 97ZA009 (AY118166), and 97ZA012 (AF286227) for subtype C references, and DH12.3 (AF069140), JR-FL (U63632), ADA.AD8 (AF004394), SF162 (EU123924), HXB2 (K03455), and SHIV KS661 for subtype B references. Phylogenetic analysis by neighbor-joining method (Saitou and Nei, 1987) was conducted using Clustal X software. The analyzed result was plotted by Mega 5 software (Tamura et al., 2011).

#### Replication kinetics of SHIV 97ZA012

Virus stocks subjected to comparison were normalized to the infectious titer (MOI=0.01 or 0.1 TCID<sub>50</sub>/cell). For infection of M8166-CCR5 cells, HIV-1 97ZA012, SHIV KS661, and SHIV 97ZA012 were titrated using TZM-bl cells, which were granted from the NIH AIDS Research & Reference Reagent Program. For infection of RhPBMCs, SIV239 and SHIV 97ZA012 were titrated in RhPBMCs. The virus stocks were inoculated to C8166-CCR5 cells or RhPBMCs by spinoculation (O'Doherty et al., 2000) at 1200  $\times$  g for 60 min.

After inoculation, culture supernatant was replaced daily with freshly prepared medium and stored at  $-20^\circ\text{C}$  until analysis of its RT activity. The AUC of the replication kinetics, an estimate of the total production of progeny virus during the observation period, was calculated for each virus using the Prism 4 Software (GraphPad Software, Inc., La Jolla, CA, USA).

#### Co-receptor usage assay

The co-receptor preference of SHIV 97ZA012 on RhPBMCs was analyzed as described previously (Matsuda et al., 2010), with the modifications described below. Infectious titers of SHIV 97ZA012, SIV239, and SHIV DH12R CL7 were normalized by the infectious titer (MOI=0.03 TCID<sub>50</sub>/cell) in this study. In the presence of 5  $\mu$ M of the small-molecule co-receptor inhibitors AMD3100 (De Clercq et al., 1994) (Sigma-Aldrich, St. Louis, MO, USA), AD101 (Trkola et al., 2002), or both, the viruses were spinoculated (1200  $\times$  g for 60 min) into RhPBMCs, and virus replication was monitored for 7 days. During the experiment, culture supernatant was replaced on days 1, 3, and 5 with freshly prepared culture medium containing the same concentration of corresponding inhibitor(s). Culture supernatant was collected on days 1, 3, 5, and 7 and stored at  $-20^\circ\text{C}$  until assessment of RT activity. Dr. Julie Strizki, Schering-Plough Research Institute, Kenilworth, NJ, generously provided the AD101.

#### Replication of SHIV 97ZA012 in RhAMs

RhAMs were collected and cultured as described above. SHIV 97ZA012, SIV239, SIV316, and SHIV  $\lambda$ 3-3 were normalized by RT activity (MOI=17 cpm equivalent/cell) and spinoculated (1200  $\times$  g for 60 min) to  $5 \times 10^5$  cells in a 24-well plate. Culture supernatant was replaced every other day with freshly prepared medium and stored at  $-20^\circ\text{C}$  until assessment of its RT activity.

#### Experimental infection of rhesus monkeys with SHIV 97ZA012

Rhesus macaques of Indian origin, approximately 4 kg in body weight, were used for experimental infection with SHIV 97ZA012. Phlebotomy, bronchoalveolar lavage, lymph node biopsy, and virus inoculation were conducted under anesthesia by intramuscular injection of a mixture of ketamine chloride (Ketalar; Daiichi Sankyo, Tokyo, Japan) at 5–10 mg/kg and xylazine chloride (Celactal; Bayer Healthcare, Leverkusen, Germany) at 1.5–2.0 mg/kg. Animals 533, 535, and 536 were intravenously inoculated with  $1 \times 10^5$  TCID<sub>50</sub> SHIV 97ZA012. Animal 554 intravenously received a mixture of anticoagulated whole blood (10 ml) and lymph node cells ( $5 \times 10^8$  cells) collected from animals 535 and 536 at 10.7 weeks post-inoculation. All animal experiments were conducted in a biosafety level 3 animal facility in compliance with institutional regulations approved by the Committee for Experimental Use of Nonhuman Primates of the Institute for Virus Research, Kyoto University, Kyoto, Japan.

## Acknowledgments

The authors thank Drs. Julie Strizki and Paul Zavodny for providing AD101, the NIH AIDS Research & Reference Reagent Program for providing primary isolates of HIV-1 and TZM-bl cells, Dr. A. Nomoto for continuous support, and members of the Igarashi laboratory for assistance with animal procedures and analyses. This work was supported by a Research on HIV/AIDS grant [awarded to T.M. and T.I., independently] from The Ministry of Health, Labor and Welfare of Japan, and by a Grant-in-Aid for Scientific Research (B) [awarded to T.M. and T.I., independently] from the Japan Society for the Promotion of Science.

## References

- Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H., Beilman, G.J., Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., Douek, D.C., 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *J. Exp. Med.* 200, 749–759.
- Broder, C.C., Jones-Trower, A., 1999. Coreceptor Use by Primate Lentiviruses, Human Retroviruses and AIDS. Theoretical Biology and Biophysics Group. Los Alamos National Laboratory, Los Alamos, NM.
- Carr, J.K., Avila, M., Gomez Carrillo, M., Salomon, H., Hierholzer, J., Watanaveeradej, V., Pando, M.A., Negrete, M., Russell, K.L., Sanchez, J., Bix, D.L., Andrade, R., Vinales, J., McCutchan, F.E., 2001. Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. *Aids* 15, F41–47.
- Chen, Z., Huang, Y., Zhao, X., Skulsky, E., Lin, D., Ip, J., Gettie, A., Ho, D.D., 2000. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (*Macaca nemestrina*). *J. Virol.* 74, 6501–6510.
- Cheng-Mayer, C., Quiroga, M., Tung, J.W., Dina, D., Levy, J.A., 1990. Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. *J. Virol.* 64, 4390–4398.
- Clavel, F., Hoggan, M.D., Willey, R.L., Strebel, K., Martin, M.A., Repaske, R., 1989. Genetic recombination of human immunodeficiency virus. *J. Virol.* 63, 1455–1459.
- De Clercq, E., Yamamoto, N., Pauwels, R., Balzarini, J., Witvrouw, M., De Vreese, K., Debyser, Z., Rosenwirth, B., Peichl, P., Datema, R., et al., 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. *Antimicrob. Agents Chemother.* 38, 668–674.
- Desrosiers, R.C., Hansen-Moosa, A., Mori, K., Bouvier, D.P., King, N.W., Daniel, M.D., Ringler, D.J., 1991. Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS. *Am. J. Pathol.* 139, 29–35.
- DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., Calos, M.P., 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol. Cell. Biol.* 7, 379–387.
- Gorry, P.R., Bristol, G., Zack, J.A., Ritola, K., Swannstrom, R., Birch, C.J., Bell, J.E., Bannert, N., Crawford, K., Wang, H., Schols, D., De Clercq, E., Kunstman, K., Wolinsky, S.M., Gabuzda, D., 2001. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. *J. Virol.* 75, 10073–10089.
- Guimaraes, M.L., Eyer-Silva, W.A., Couto-Fernandez, J.C., Morgado, M.G., 2008. Identification of two new CRF\_BF in Rio de Janeiro State, Brazil. *Aids* 22, 433–435.
- Harouse, J.M., Gettie, A., Eshetu, T., Tan, R.C., Bohm, R., Blanchard, J., Baskin, G., ChengMayer, C., 2001. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). *J. Virol.* 75, 1990–1995.
- Hemelaar, J., Gouws, E., Ghys, P.D., Osmanov, S., 2011. Global trends in molecular epidemiology of HIV-1 during 2000–2007. *Aids* 25, 679–689.
- Hertogs, K., de Bethune, M.P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van Den Eynde, C., Van Gerwen, V., Azijn, H., Van Houtte, M., Peeters, F., Staszewski, S., Conant, M., Bloor, S., Kemp, S., Larder, B., Pauwels, R., 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. *Antimicrob. Agents Chemother.* 42, 269–276.
- Hirsch, V., Adger-Johnson, D., Campbell, B., Goldstein, S., Brown, C., Elkins, W.R., Montefiori, D.C., 1997. A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. *J. Virol.* 71, 1608–1620.
- Igarashi, T., Endo, Y., Englund, G., Sadjadpour, R., Matano, T., Buckler, C., Buckler-White, A., Plishka, R., Theodore, T., Shibata, R., Martin, M., 1999. Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. *Proc. Natl. Acad. Sci. USA* 96, 14049–14054.
- Igarashi, T., Donau, O.K., Imamichi, H., Nishimura, Y., Theodore, T.S., Iyengar, R., Erb, C., Buckler-White, A., Buckler, C.E., Martin, M.A., 2007. Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques. *J. Virol.* 81, 10669–10679.
- Igarashi, T., Donau, O.K., Matsuyama, M., Unpublished Results.
- Imamichi, H., Igarashi, T., Imamichi, T., Donau, O.K., Endo, Y., Nishimura, Y., Willey, R.L., Suffredini, A.F., Lane, H.C., Martin, M.A., 2002. Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. *Proc. Natl. Acad. Sci. USA* 99, 13813–13818.
- Inoue, M., Hoxie, J.A., Reddy, M.V., Srinivasan, A., Reddy, E.P., 1991. Mechanisms associated with the generation of biologically active human immunodeficiency virus type 1 particles from defective proviruses. *Proc. Natl. Acad. Sci. USA* 88, 2278–2282.
- Joag, S.V., Li, Z., Foresman, L., Stephens, E.B., Zhao, L.J., Adany, I., Pinson, D.M., McClure, H.M., Narayan, O., 1996. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. *J. Virol.* 70, 3189–3197.
- John-Stewart, G.C., Nduati, R.W., Rousseau, C.M., Mbori-Ngacha, D.A., Richardson, B.A., Rainwater, S., Panteleeff, D.D., Overbaugh, J., 2005. Subtype C is associated with increased vaginal shedding of HIV-1. *J. Infect. Dis.* 192, 492–496.
- Kalyanaraman, S., Jannoun-Nasr, R., York, D., Luciw, P.A., Robinson, R., Srinivasan, A., 1988. Homologous recombination between human immunodeficiency viral DNAs in cultured human cells: analysis of the factors influencing recombination. *Biochem. Biophys. Res. Commun.* 157, 1051–1060.
- Kamada, K., Igarashi, T., Martin, M.A., Khamsri, B., Hatcho, K., Yamashita, T., Fujita, M., Uchiyama, T., Adachi, A., 2006. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. *Proc. Natl. Acad. Sci. USA* 103, 16959–16964.
- Kellam, P., Larder, B.A., 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. *Antimicrob. Agents Chemother.* 38, 23–30.
- Kestler 3rd, H.W., Li, Y., Naidu, Y.M., Butler, C.V., Ochs, M.F., Jaenel, G., King, N.W., Daniel, M.D., Desrosiers, R.C., 1988. Comparison of simian immunodeficiency virus isolates. *Nature* 331, 619–622.
- Kouliniska, I.N., Ndung'u, T., Mwakagile, D., Msamanga, G., Kagoma, C., Fawzi, W., Essex, M., Renjifo, B., 2001. A new human immunodeficiency virus type 1 circulating recombinant form from Tanzania. *AIDS Res. Hum. Retroviruses* 17, 423–431.
- Kuwata, T., Takemura, T., Takehisa, J., Miura, T., Hayami, M., 2002. Infection of macaques with chimeric simian and human immunodeficiency viruses containing Env from subtype F. *Arch. Virol.* 147, 1121–1132.
- Li, J., Lord, C.I., Haseltine, W., Letvin, N.L., Sodroski, J., 1992. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. *J. Acquired Immune Defic. Syndromes* 5, 639–646.
- Lole, K.S., Bollinger, R.C., Paranjape, R.S., Gadkari, D., Kulkarni, S.S., Novak, N.G., Ingersoll, R., Sheppard, H.W., Ray, S.C., 1999. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. *J. Virol.* 73, 152–160.
- Luciw, P.A., Pratt-Lowe, E., Shaw, K.E., Levy, J.A., Cheng-Mayer, C., 1995. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). *Proc. Natl. Acad. Sci. USA* 92, 7490–7494.
- Mao, Z., Jiang, Y., Liu, X., Seluanov, A., Gorbunova, V., 2009. DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. *Neoplasia* 11, 683–691.
- Matsuda, K., Inaba, K., Fukazawa, Y., Matsuyama, M., Ibuki, K., Horiike, M., Saito, N., Hayami, M., Igarashi, T., Miura, T., 2010. *In vivo* analysis of a new R5 tropic SHIV generated from the highly pathogenic SHIV-KS661, a derivative of SHIV-89.6. *Virology* 399, 134–143.
- Miller, C.J., Marthas, M., Greenier, J., Lu, D., Dailey, P.J., Lu, Y., 1998. *In vivo* replication capacity rather than *in vitro* macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. *J. Virol.* 72, 3248–3258.
- Moore, P.L., Gray, E.S., Choge, I.A., Ranchobe, N., Mlisana, K., Abdool Karim, S.S., Williamson, C., Morris, L., 2008. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. *J. Virol.* 82, 1860–1869.
- Mori, K., Ringler, D.J., Desrosiers, R.C., 1993. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. *J. Virol.* 67, 2807–2814.
- Mori, K., Rosenzweig, M., Desrosiers, R.C., 2000. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. *J. Virol.* 74, 10852–10859.
- Ng, O.T., Eyzaguirre, L.M., Carr, J.K., Chew, K.K., Lin, L., Chua, A., Leo, Y.S., Redd, A.D., Quinn, T.C., Laeyendecker, O., 2012. Identification of new CRF51\_01B in Singapore using full genome analysis of three HIV type 1 isolates. *AIDS Res. Hum. Retroviruses* 28, 527–530.
- Nishimura, Y., Shingai, M., Willey, R., Sadjadpour, R., Lee, W.R., Brown, C.R., Brenchley, J.M., Buckler-White, A., Petros, R., Eckhaus, M., Hoffman, V., Igarashi, T., Martin, M.A., 2010. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. *J. Virol.* 84, 4769–4781.
- O'Doherty, U., Swiggard, W.J., Malim, M.H., 2000. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. *J. Virol.* 74, 10074–10080.

- Okoye, A., Meier-Schellersheim, M., Brenchley, J.M., Hagen, S.I., Walker, J.M., Rohankhedkar, M., Lum, R., Edgar, J.B., Planer, S.L., Legasse, A., Sylwester, A.W., Piatak Jr., M., Lifson, J.D., Maino, V.C., Sodora, D.L., Douek, D.C., Axthelm, M.K., Grossman, Z., Picker, L.J., 2007. Progressive CD4<sup>+</sup> central memory T cell decline results in CD4<sup>+</sup> effector memory insufficiency and overt disease in chronic SIV infection. *The Journal of experimental medicine* 204, 2171–2185.
- Perez, L., Thomson, M.M., Bleda, M.J., Aragones, C., Gonzalez, Z., Perez, J., Sierra, M., Casado, G., Delgado, E., Najera, R., 2006. HIV Type 1 molecular epidemiology in Cuba: high genetic diversity, frequent mosaicism, and recent expansion of BG intersubtype recombinant forms. *AIDS Res. Hum. Retroviruses* 22, 724–733.
- Piyasirisilp, S., McCutchan, F.E., Carr, J.K., Sanders-Buell, E., Liu, W., Chen, J., Wagner, R., Wolf, H., Shao, Y., Lai, S., Beyrer, C., Yu, X.F., 2000. A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant. *J. Virol.* 74, 11286–11295.
- Puffer, B.A., Pohlmann, S., Edinger, A.L., Carlin, D., Sanchez, M.D., Reitter, J., Watry, D.D., Fox, H.S., Desrosiers, R.C., Doms, R.W., 2002. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. *J. Virol.* 76, 2595–2605.
- Reimann, K.A., Li, J.T., Veazey, R., Halloran, M., Park, I.W., Karlsson, G.B., Sodroski, J., Letvin, N.L., 1996a. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after *in vivo* passage in rhesus monkeys. *J. Virol.* 70, 6922–6928.
- Reimann, K.A., Li, J.T., Voss, G., Lekutis, C., TennerRacz, K., Racz, P., Lin, W., Montefiori, D.C., LeeParritz, D.E., Lu, Y., Collman, R.G., Sodroski, J., Letvin, N.L., 1996b. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high *in vivo* replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. *J. Virol.* 70, 3198–3206.
- Sadjadpour, R., Theodore, T.S., Igarashi, T., Donau, O.K., Plishka, R.J., Buckler-White, A., Martin, M.A., 2004. Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic. *J. Virol.* 78, 5513–5519.
- Saitou, N., Nei, M., 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* 4, 406–425.
- Sakuragi, S., Shibata, R., Mukai, R., Komatsu, T., Fukasawa, M., Sakai, H., Sakuragi, J., Kawamura, M., Ibuki, K., Hayami, M., 1992. Infection of macaque monkeys with a chimeric human and simian immunodeficiency virus. *J. Gen. Virol.* 73 (Pt 11), 2983–2987.
- Sharma, D.P., Zink, M.C., Anderson, M., Adams, R., Clements, J.E., Joag, S.V., Narayan, O., 1992. Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytotropic parental virus: pathogenesis of infection in macaques. *J. Virol.* 66, 3550–3556.
- Shibata, R., Kawamura, M., Sakai, H., Hayami, M., Ishimoto, A., Adachi, A., 1991. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. *J. Virol.* 65, 3514–3520.
- Shibata, R., Maldarelli, F., Siemon, C., Matano, T., Parta, M., Miller, G., Fredrickson, T., Martin, M.A., 1997. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. *J. Infect. Dis.* 176, 362–373.
- Shinohara, K., Sakai, K., Ando, S., Ami, Y., Yoshino, N., Takahashi, E., Someya, K., Suzuki, Y., Nakasone, T., Sasaki, Y., Kaizu, M., Lu, Y., Honda, M., 1999. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. *J. Gen. Virol.* 80 (Pt 5), 1231–1240.
- Soda, Y., Shimizu, N., Jinno, A., Liu, H.Y., Kanbe, K., Kitamura, T., Hoshino, H., 1999. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. *Biochem. Biophys. Res. Commun.* 258, 313–321.
- Song, R.J., Chenine, A.L., Rasmussen, R.A., Ruprecht, C.R., Mirshahidi, S., Grisson, R.D., Xu, W., Whitney, J.B., Goins, L.M., Ong, H., Li, P.L., ShaiKobiler, E., Wang, T., McCann, C.M., Zhang, H., Wood, C., Kankasa, C., Secor, W.E., McClure, H.M., Strobert, E., Else, J.G., Ruprecht, R.M., 2006. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. *J. Virol.* 80, 8729–8739.
- Srinivasan, A., York, D., Jannoun-Nasr, R., Kalyanaraman, S., Swan, D., Benson, J., Bohan, C., Luciw, P.A., Schnoll, S., Robinson, R.A., et al., 1989. Generation of hybrid human immunodeficiency virus by homologous recombination. *Proc. Natl. Acad. Sci. USA* 86, 6388–6392.
- Su, L., Graf, M., Zhang, Y., von Briesen, H., Xing, H., Kostler, J., Melzl, H., Wolf, H., Shao, Y., Wagner, R., 2000. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain in China. *J. Virol.* 74, 11367–11376.
- Takai, T., Ohmori, H., 1990. DNA transfection of mouse lymphoid cells by the combination of DEAE-dextran-mediated DNA uptake and osmotic shock procedure. *Biochim. Biophys. Acta* 1048, 105–109.
- Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., Kumar, S., 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol. Biol. Evol.* 28, 2731–2739.
- Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G., 1997. The CLUSTAL\_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. *Nucl. Acids Res.* 25, 4876–4882.
- Trkola, A., Kuhmann, S.E., Strizki, J.M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., Palani, A., Shapiro, S., Clader, J.W., McCombie, S., Reyes, G.R., Baroudy, B.M., Moore, J.P., 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. *Proc. Natl. Acad. Sci. USA* 99, 395–400.
- UNAIDS, 2010. Report on the Global Aids Epidemic.
- Veazey, R.S., DeMaria, M., Chalifoux, L.V., Shvets, D.E., Pauley, D.R., Knight, H.L., Rosenzweig, M., Johnson, R.P., Desrosiers, R.C., Lackner, A.A., 1998. Gastrointestinal tract as a major site of CD4<sup>+</sup> T cell depletion and viral replication in SIV infection. *Science* 280, 427–431.
- Veazey, R.S., Marx, P.A., Lackner, A.A., 2003. Vaginal CD4<sup>+</sup> T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. *J. Infect. Dis.* 187, 769–776.
- Vispe, S., Cazaux, C., Lesca, C., Defais, M., 1998. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. *Nucl. Acids Res.* 26, 2859–2864.
- Walter, B.L., Armitage, A.E., Graham, S.C., de Oliveira, T., Skinhoj, P., Jones, E.Y., Stuart, D.I., McMichael, A.J., Chesebro, B., Iversen, A.K., 2009. Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility. *Aids* 23, 1047–1057.
- Willey, R.L., Smith, D.H., Lasky, L.A., Theodore, T.S., Earl, P.L., Moss, B., Capon, D.J., Martin, M.A., 1988. *In vitro* mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. *J. Virol.* 62, 139–147.
- Worgall, S., Connor, R., Kaner, R.J., Fenamore, E., Sheridan, K., Singh, R., Crystal, R.G., 1999. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. *J. Virol.* 73, 5865–5874.
- Yamaguchi, J., Badreddine, S., Swanson, P., Bodelle, P., Devare, S.G., Brennan, C.A., 2008. Identification of new CRF43\_02G and CRF25\_cpx in Saudi Arabia based on full genome sequence analysis of six HIV type 1 isolates. *AIDS Res. Hum. Retroviruses* 24, 1327–1335.
- Zhang, Y., Lou, B., Lal, R.B., Gettie, A., Marx, P.A., Moore, J.P., 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. *J. Virol.* 74, 6893–6910.